ClinicalTrials.Veeva

Menu

Audio-visual Stimulation for Sleep Promotion in Older Adults With Osteoarthritis Pain

University of Washington logo

University of Washington

Status

Completed

Conditions

Osteoarthritis
Pain, Chronic
Insomnia Chronic

Treatments

Device: Audiovisual Stimulation

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Background and Purpose: The purpose of the study is to test the efficacy of an audio-visual stimulation program for sleep promotion in adults with chronic pain. The hypothesis is that hyper-arousal plays an important role in insomnia. Brainwave entrainment from 8 to 1 Hz reduces arousal, and thereby improves sleep. Improved sleep may change how people perceive pain.

Methods: Using a double-blind, randomized controlled trial design, we plan to enroll 30 adults (21-65 years old) experiencing both nonmalignant pain and insomnia. Exclusion criteria include: seizure disorder, sleep disorder, and night shift workers. After a one-week baseline measure, participants will be randomized to intervention or placebo group. Participants in both groups will be asked to self-administer the audio-visual stimulation program every night at bedtime for one month. Upon completion, post intervention measures will be collected.

Full description

Background: The purpose of this pilot study was to test the efficacy of an open-looped Audio-visual Stimulation program (AVS) for sleep promotion in older adults with osteoarthritis pain. In this study, the AVS program was tested in a randomized controlled design. Specifically, this pilot study examined a 30-minute audio-visual stimulation program that gradually ramped from 10 Hz down to 2 Hz, to be used at bedtime for delta brainwave induction, in a randomized controlled design. The placebo control AVS program consisted of 30-minutes of constant dim light that slowly changed in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).

Method: A total of 30 older adults (mean age 68 ± 5.1, 90% women) with comorbid insomnia and osteoarthritis pain participated in this 2-week study. Participants were randomly assigned to either AVS active program or AVS placebo control program. After the baseline assessment (which included questionnaires [sleep, pain, depression], and quantitative electroencephalogram (QEEG) during AVS induction), participants were asked to self-administer their group specific AVS program nightly at bedtime for two weeks. Post-treatment questionnaires (sleep, pain, depression) were then collected.

Enrollment

30 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 60 years or older
  • Having difficulty sleeping over the past three months (Insomnia Severity Index ≥ 8)
  • Having osteoarthritis pain (Brief Pain Inventory Worst pain ≥ 4)

Exclusion criteria

  • Working night shift
  • Previously diagnosed with a primary sleep disorder (Sleep Apnea or Restless Leg Syndrome).
  • Seizure disorder
  • Photosensitivity
  • Dementia
  • Diagnosis or other significant chronic illness beyond OA that would impact sleep
  • Severe psychiatric disorder including a history of or current diagnosis of psychosis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

30 participants in 2 patient groups, including a placebo group

Active AVS
Experimental group
Description:
Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
Treatment:
Device: Audiovisual Stimulation
Placebo Control AVS
Placebo Comparator group
Description:
The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (\<1 Hz) frequency (outside of the entrainment range).
Treatment:
Device: Audiovisual Stimulation

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems